Advertisement

Topics

Pfizer Reports European Commission's Approval Of BESPONSA

08:00 EDT 30 Jun 2017 | FinanzNachrichten

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced the European Commission has approved BESPONSA as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell prec...

Original Article: Pfizer Reports European Commission's Approval Of BESPONSA

NEXT ARTICLE

More From BioPortfolio on "Pfizer Reports European Commission's Approval Of BESPONSA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...